Deals this week: Blue Earth Diagnostics, Implanet, One BioMed

1 June 2017 (Last Updated June 1st, 2017 18:30)

Blue Earth Diagnostics has granted distribution rights of its positron emission tomography (PET) imaging product, Axumin (fluciclovine -18F), to Advanced Accelerator Applications.

Blue Earth Diagnostics has granted distribution rights of its positron emission tomography (PET) imaging product, Axumin (fluciclovine -18F), to Advanced Accelerator Applications.

Advanced Accelerator Applications will distribute Axumin, which was recently approved by European Commission, in France, Germany, Spain, Italy, and Portugal.

The product is indicated for use in PET imaging to detect recurrence of prostate cancer in adult men.

Dental implants manufacturer Implanet has raised gross proceeds of $162.78m through a public offering of 150 convertible bonds.

The profits from the offering will be used to develop and commercialise its new orthopaedic implant, JAZZ Band.

In a move to develop novel point-of-care molecular diagnostics platforms, Genome Institute of Singapore (GIS) and One BioMed have formed a new joint venture (JV).

The JV will develop a new laboratory at the Biopolis, Genome’s research and development centre in Singapore.

The lab will aim to advance molecular diagnostic assays using One BioMed’s platform for the Asian clinical infectious disease testing market.

"The product is indicated for use in PET imaging to detect recurrence of prostate cancer in adult men."

The assays will address clinically important diseases such as paediatric respiratory infections, drug-resistant tuberculosis and mosquito-borne illnesses in Asia.

Orion Health Group intends to raise $22.4m by offering 36,555,555 shares of its common stock at a price of $0.63 a share. The company will offer nine shares to its shareholders for every common stock share held, while the proceeds will be used for working capital purposes.

Diagnostic reagents and equipment manufacturer Agappe Diagnostics has signed a licencing agreement with Hitachi Chemical for the development of advanced, fully-automatic specific protein and clinical chemistry analysers in India.

The diagnostics solutions developed by the two companies will help detect kidney malfunction, cardiac problems and osteoporosis in early stages, and will be affordable to the rural population.

In series D equity financing, Saluda Medical has raised $39.44m, which will be used to support the clinical trial and commercialisation of its Evoke spinal cord stimulation (SCS) system in Europe and Australia.

Evoke SCS system is an investigational device for chronic back and leg pain.

Led by Action Potential Venture Capital, the round has also seen the participation of existing investors, including Medtronic Plc.